[Federal Register Volume 87, Number 187 (Wednesday, September 28, 2022)]
[Notices]
[Pages 58800-58801]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-20985]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-1914]


Clinical Chemistry and Clinical Toxicology Devices Panel of the 
Medical Devices Advisory Committee; Notice of Meeting; Establishment of 
a Public Docket; Request for Comments; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

[[Page 58801]]


ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing a 
correction to the notice of meeting of the Clinical Chemistry and 
Clinical Toxicology Devices Panel of the Medical Devices Advisory 
Committee. This meeting was announced in the Federal Register of 
September 2, 2022. The correction is being made to reflect a change to 
the sponsor's name. There are no other changes.

FOR FURTHER INFORMATION CONTACT: James Swink, Center for Devices and 
Radiological Health, Food and Drug Administration, 10903 New Hampshire 
Ave., Bldg. 66, Rm. 5211, Silver Spring, MD 20993-0002, 301-796-6313, 
[email protected], or FDA Advisory Committee Information Line, 1-
800-741-8138 (301-443-0572 in the Washington, DC area). Please call the 
Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of September 2, 2022 
(87 FR 54221), FDA announced that a meeting of the Clinical Chemistry 
and Clinical Toxicology Devices Panel of the Medical Devices Advisory 
Committee would be held on October 20, 2022. On page 54222, in the 
second column, in the Agenda portion of the document, the second 
sentence ``On October 20, 2022, the committee will discuss, make 
recommendations, and vote on clinical information related to the De 
Novo request for the AvertD Test sponsored by SolvD, Inc.'' is changed 
to read as follows: ``On October 20, 2022, the committee will discuss, 
make recommendations, and vote on clinical information related to the 
De Novo request for the AvertD Test sponsored by SOLVD Health.''
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: September 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-20985 Filed 9-27-22; 8:45 am]
BILLING CODE 4164-01-P


